{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,25]],"date-time":"2024-08-25T19:07:10Z","timestamp":1724612830110},"reference-count":28,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2004,7,20]],"date-time":"2004-07-20T00:00:00Z","timestamp":1090281600000},"content-version":"vor","delay-in-days":49,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[2004,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Detection of minimal residual disease (MRD) in patients with B\u2010cell acute lymphoblastic leukemia (B\u2010ALL) has been achieved using several radioactive labelling methodologies; however, limited information exists about the use of chemiluminescent labelling. Although many malignant disorders are related to cytogenetic alterations, there is not a consistent chromosomal translocation that could serve as a tumour marker for the monitoring of MRD. ALL are derived from B\u2010lymphocytes in 80% of cases. In the early stages of their maturation, the immunoglobulin heavy chain genes (IgH) undergo rearrangements among their V, D, and J segments, giving rise to the Complementary Determining Regions (CDR). Among these, CDR3 is considered unique for each lymphocyte and used as a tumour\u2010specific marker in B\u2010ALL patients. In this study, the CDR3 was labelled with digoxigenin and used as a patient\u2010specific probe to test its sensitivity for further detection of MRD. Fourteen pretreatment samples of bone marrow (BM) or peripheral blood (PB) from B\u2010ALL patients were included. Tumour\u2010specific probes were designed from each clonal product by elimination of the consensus sequences. Ten digoxigenin\u2010labelled probes were hybridized with a mixture of their respective clonal DNA and the polyclonal product from a normal healthy donor, in serial dilutions from 1:1 up to 1:10<jats:sup>7<\/jats:sup>. A sensitivity range of 1:10<jats:sup>3<\/jats:sup>\u20131:10<jats:sup>6<\/jats:sup> was obtained, with an average of 1:10<jats:sup>5<\/jats:sup>. Crossed tests performed in four patients, showed right probe specificity in all cases. We propose that the design of allele\u2010specific probes with chemiluminescent labelling, represents a reliable, sure and sensitive alternative methodology for MRD detection in patients with B\u2010cell lymphoproliferative disorders. Copyright \u00a9 2004 John Wiley &amp; Sons, Ltd.<\/jats:p>","DOI":"10.1002\/hon.727","type":"journal-article","created":{"date-parts":[[2004,7,20]],"date-time":"2004-07-20T10:00:32Z","timestamp":1090317632000},"page":"55-61","source":"Crossref","is-referenced-by-count":3,"title":["High sensitivity of chemiluminescent methodology for detection of clonal CDR3 sequences in patients with acute lymphoblastic leukemia"],"prefix":"10.1002","volume":"22","author":[{"given":"E.","family":"Leal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. R.","family":"Jaloma\u2010Cruz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Barros\u2010N\u00fa\u00f1ez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2004,7,20]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)04058-6"},{"key":"e_1_2_1_3_2","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1182\/blood.V92.3.952","article-title":"Clonal diversity of Ig and T\u2010cell\u2010receptor gene rearrangements identifies a subset of childhood B\u2010precursor acute lymphoblastic leukemia with increased risk of relapse","volume":"3","author":"Green E","year":"1998","journal-title":"Blood"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(01)00072-8"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401246"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199909093724"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2400542"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V76.8.1449.1449"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/302575a0"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.86.13.5123"},{"key":"e_1_2_1_11_2","first-page":"289","article-title":"Detection of clonality in childhood B\u2010lineage acute lymphoblastic leukemia by the polymerase chain reaction","volume":"6","author":"Potter MN","year":"1992","journal-title":"Leukemia"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1990.tb02643.x"},{"key":"e_1_2_1_13_2","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1182\/blood.V82.5.1618.1618","article-title":"Long\u2010term follow\u2010up of residual disease in acute lymphoblastic leukemia patients in complete remission using clonogeneic IgH probes and the polymerase chain reaction","volume":"82","author":"Nizet Y","year":"1993","journal-title":"Blood"},{"key":"e_1_2_1_14_2","first-page":"615","article-title":"Prospective monitoring of minimal residual disease during the course of chemotherapy in patients with acute lymphoblastic leukemia, and detection of contaminating tumor cells in peripheral blood stem cells for autotransplantation","volume":"9","author":"Seriu T","year":"1995","journal-title":"Leukemia"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.512699.x"},{"key":"e_1_2_1_16_2","first-page":"3957","article-title":"Improved quantitation of minimal residual disease in multiple myeloma using real\u2010time polymerase chain reaction and plasmid\u2013DNA complementarity determining region III standards","volume":"58","author":"Gerard CJ","year":"1998","journal-title":"Cancer Res"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401831"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401801"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0301-472X(02)00892-5"},{"key":"e_1_2_1_20_2","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1182\/blood.V95.8.2651","article-title":"Immunoglobulin heavy\u2010chain consensus probes for real\u2010time PCR quantification of residual disease in acute lymphoblastic leukemia","volume":"95","author":"Donovan JW","year":"2000","journal-title":"Blood"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2000.02029.x"},{"key":"e_1_2_1_22_2","first-page":"3281","article-title":"Rapid and reliable quantification of minimal residual disease in acute lymphoblastic leukemia using rearranged immunoglobulin and T\u2010cell receptor loci by LightCycler technology","volume":"60","author":"Nakao M","year":"2000","journal-title":"Cancer Res"},{"key":"e_1_2_1_23_2","first-page":"1314","article-title":"Application of chemiluminescent methodology for detection of minimal residual disease in childhood acute lymphoblastic leukemia","volume":"86","author":"Lo Nigro L","year":"2001","journal-title":"Haematologica"},{"issue":"77","key":"e_1_2_1_24_2","article-title":"Separation of leucocytes from blood and bone marrow","volume":"21","author":"Boyum A","year":"1968","journal-title":"Scand J Clin Lab Invest"},{"key":"e_1_2_1_25_2","volume-title":"Molecular Cloning: Laboratory Manual","author":"Sambrook J","year":"2001"},{"key":"e_1_2_1_26_2","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1182\/blood.V82.1.202.bloodjournal821202","article-title":"Advancement of multiple myeloma from diagnosis through plateau phase to progression does not involve a new B\u2010cell clone: evidence from the Ig heavy chain gene","volume":"82","author":"Quentin MR","year":"1993","journal-title":"Blood"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/hon.701"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402736"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1309\/G6299513NGLCUB1K"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhon.727","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.727","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T12:38:44Z","timestamp":1700224724000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.727"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,6]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2004,6]]}},"alternative-id":["10.1002\/hon.727"],"URL":"https:\/\/doi.org\/10.1002\/hon.727","archive":["Portico"],"relation":{},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,6]]}}}